Latest Period
Q1 2026
Security Snapshot
Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX) Institutional Ownership
CUSIP: 055477103
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
145
Shares (Excl. Options)
70,083,459
Price
$19.89
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- BCAX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 70,083,459
- Total 13F value
- $1,392,832,468
- Portfolio coverage rank
- 0.01%
- Share change
- +9,372,052
- Value change
- +$187,868,786
- Number of holders
- 145
- Shares outstanding
- 65,361,446
- SEC-reported price per share
- $20.23
- Insider filing price
- $20.23
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BCAX - Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 055477103.
- 145 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 141 to 145 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $960,809,484 to $1,392,832,468.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 145 institutions filings for Q1 2026.
Security key
055477103
Latest holder period
Q1 2026
13F holders
145
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
BCAX full holder history
Bicara Therapeutics Inc. SEC filings
Bicara Therapeutics Inc. company facts
Bicara Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 055477103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
BCAX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12% | $123,100,386 | 7,279,739 | RA Capital Management, L.P. | 26 Feb 2026 | |||
| T. Rowe Price Investment Management, Inc. | 10% | +70% | $131,386,982 | +$67,012,079 | 6,605,780 | +104% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
| Vestal Point Capital, LP | 8.3% | +26% | $120,109,500 | +$40,959,000 | 5,425,000 | +52% | Vestal Point Capital, LP | 31 Mar 2026 |
| Invus Global Management, LLC | 9.6% | $50,656,769 | 5,216,969 | Raymond Debbane | 30 Jun 2025 | |||
| Deep Track Capital, LP | 6.2% | +24% | $89,943,750 | +$29,058,750 | 4,062,500 | +48% | Deep Track Capital, LP | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 5.1% | $73,930,287 | 3,339,218 | JANUS HENDERSON GROUP PLC | 31 Mar 2026 | |||
| Red Tree GP, LLC | 4.8% | $70,195,069 | 3,170,509 | Red Tree GP, LLC | 31 Mar 2026 | |||
| FMR LLC | 3.2% | -48% | $46,514,568 | -$27,592,949 | 2,100,929 | -37% | FMR LLC | 31 Mar 2026 |
As of 31 Mar 2026, 145 institutional investors reported holding 70,083,459 shares of Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX). This represents 107% of the company’s total 65,361,446 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
95%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | 7,255,993 | +4.3% | 1.5% | $144,321,701 |
| T. Rowe Price Investment Management, Inc. | 10% | 6,605,780 | +104% | 0.09% | $131,389,000 |
| Siren, L.L.C. | 8.9% | 5,802,970 | +11% | 3.2% | $115,421,073 |
| Vestal Point Capital, LP | 8.3% | 5,425,000 | +52% | 3% | $107,903,250 |
| Deep Track Capital, LP | 6.2% | 4,062,500 | +55% | 1.7% | $80,803,125 |
| JANUS HENDERSON GROUP PLC | 5.1% | 3,339,218 | +26% | 0.03% | $66,350,262 |
| RED TREE MANAGEMENT, LLC | 4.9% | 3,170,509 | 0% | 56% | $63,061,424 |
| TPG GP A, LLC | 4.6% | 3,010,425 | 0% | 1.6% | $59,877,353 |
| BlackRock, Inc. | 4.4% | 2,843,707 | +12% | 0% | $56,561,328 |
| Omega Fund Management, LLC | 3.7% | 2,392,150 | +8.5% | 29% | $47,579,864 |
| Royalty Pharma Sub-Manager, LLC | 3.7% | 2,388,150 | 0% | 27% | $46,688,333 |
| FMR LLC | 3.2% | 2,100,929 | -37% | 0% | $41,787,477 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.7% | 1,774,220 | 0% | 0% | $35,289,236 |
| CITADEL ADVISORS LLC | 2.5% | 1,659,342 | +115% | 0.02% | $33,004,313 |
| FRANKLIN RESOURCES INC | 2.5% | 1,621,643 | +0.1% | 0.01% | $32,254,484 |
| STATE STREET CORP | 2.2% | 1,419,388 | -14% | 0% | $28,231,627 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.1% | 1,376,198 | -12% | 0% | $27,374,000 |
| Jones Hill Capital LP | 1.9% | 1,260,136 | 0% | 5.4% | $25,064,105 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 830,906 | +2.4% | 0% | $16,530,951 |
| FIL Ltd | 1% | 679,904 | -10% | 0.01% | $13,523,291 |
| ORBIMED ADVISORS LLC | 1% | 667,300 | +219% | 0.3% | $13,272,597 |
| ACORN CAPITAL ADVISORS, LLC | 0.98% | 643,382 | 0% | 3.6% | $12,796,860 |
| Aisling Capital Management LP | 0.87% | 568,919 | 0% | 2.4% | $11,315,799 |
| GOLDMAN SACHS GROUP INC | 0.86% | 558,964 | +1.2% | 0% | $11,117,794 |
| Palo Alto Investors LP | 0.84% | 550,408 | +84% | 1.7% | $10,947,615 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q1 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 70,083,459 | $1,392,832,468 | +$187,868,786 | $19.89 | 145 |
| 2025 Q4 | 57,096,026 | $960,809,484 | +$119,906,754 | $16.83 | 141 |
| 2025 Q3 | 49,994,786 | $789,088,187 | +$2,780,392 | $15.79 | 112 |
| 2025 Q2 | 51,165,684 | $475,330,436 | -$6,689,372 | $9.29 | 105 |
| 2025 Q1 | 48,567,553 | $633,357,650 | +$9,523,679 | $13.03 | 92 |
| 2024 Q4 | 46,709,070 | $813,618,424 | +$73,899,338 | $17.42 | 84 |
| 2024 Q3 | 36,408,664 | $927,393,381 | +$849,110,088 | $25.47 | 69 |